z Stealth Company
A new stealth portfolio we’re very excited about!
As a career innovator, entrepreneur, and investor, David co-founded Averin with the vision of bringing forth a new era in health–one powered by technology and that can lead to better outcomes for patients everywhere, faster, and at lower cost.
Prior to Averin, David co-founded over 30 companies across life sciences and sustainability, including 7 that were valued over $1B. He was previously a General Partner at Flagship Pioneering.
David has been broadly recognized as a world-leading innovator, having been elected as a Young Global Leader by the World Economic Forum, named an Innovator of the Year by MIT Technology Review from amongst its annual TR35 list, and selected by the U.S. State Department as one of 12 Innovators Reshaping Reality alongside pioneers such as Tim Berners-Lee. He holds over 200 patents and patent applications.
David received his M.D. from Harvard Medical School and his Ph.D. from MIT in biological engineering. He received a B.S. from MIT in Brain and Cognitive Sciences.
Portfolio Highlights
-
-
xPharma AI
xPharma makes biotech assets transactable, verifying and structuring drug programs so they can be licensed, funded, or acquired. Infrastructure for the market in science, not a bet on any single molecule.
Founded
Partnered
Hologen AI
Hologen AI is a clinical-stage artificial intelligence company that uses large-scale, multi-modal generative models — called Large Medicine Models — to optimize drug development, especially in late-stage clinical trials.
Founded
Leadership
Partnered
Biolinq
Biolinq is a complete rethink of the CGM form factor, in a way that opens it to incredible opportunities beyond the traditional use cases.
Founded
Leadership
Partnered
Freenome
A pioneering liquid biopsy company that will clear FDA approvals for cancer diagnostics, with leading sensitivity and specificity.
Founded
Leadership
Partnered
The latest from David
